Nanobiotix SA, a late-stage nanomedicine company, has appointed Edwina Baskin-Bey, a medical doctor, to replace Elsa Borghi, also a medical doctor, as chief medical officer. Dr Borghi will remain with Nanobiotix, focusing on early stage development. Dr Baskin-Bey, who has extensive experience in drug development, will be responsible for medical, regulatory, pharmacovigilance, clinical operations, biostatistics and data management functions of the company. She previously worked as CMO for a start-up biotech in North Carolina, Innocrin Pharmaceuticals Inc, after leading several prostate cancer development programmes at the Janssen Oncology unit of Johnson & Johnson.
Nanobiotix announced the appointment on 4 June 2019.
Copyright 2019 Evernow Publishing Ltd